IN2012DN02692A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02692A IN2012DN02692A IN2692DEN2012A IN2012DN02692A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A IN 2692DEN2012 A IN2692DEN2012 A IN 2692DEN2012A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A
- Authority
- IN
- India
- Prior art keywords
- subunit
- immunity against
- inducing immunity
- antigenic peptides
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25836909P | 2009-11-05 | 2009-11-05 | |
| US25872909P | 2009-11-06 | 2009-11-06 | |
| US12/754,140 US8722047B2 (en) | 2005-03-03 | 2010-04-05 | Humanized anti-HLA-DR antibodies |
| US12/754,740 US8562988B2 (en) | 2005-10-19 | 2010-04-06 | Strategies for improved cancer vaccines |
| US37805910P | 2010-08-30 | 2010-08-30 | |
| PCT/US2010/054668 WO2011056721A2 (en) | 2009-11-05 | 2010-10-29 | Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02692A true IN2012DN02692A (ru) | 2015-09-04 |
Family
ID=43970701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2692DEN2012 IN2012DN02692A (ru) | 2009-11-05 | 2010-10-29 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2496256A4 (ru) |
| CN (1) | CN102573902A (ru) |
| AU (1) | AU2010315432A1 (ru) |
| CA (1) | CA2776563A1 (ru) |
| IN (1) | IN2012DN02692A (ru) |
| WO (1) | WO2011056721A2 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3138581T3 (en) | 2011-03-17 | 2019-04-15 | Univ Birmingham | REDIRECTED IMMUNTERY |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US20150238632A1 (en) * | 2012-09-18 | 2015-08-27 | University Of Washington Through Its Center For Commercialization | Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells |
| CA2971288A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| AU2016358296B2 (en) | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN109187982B (zh) * | 2018-08-02 | 2021-06-04 | 浙江康佰裕生物科技有限公司 | 一种tlr类疫苗佐剂的筛选和鉴定方法 |
| CN109172818B (zh) * | 2018-08-02 | 2021-10-22 | 浙江康佰裕生物科技有限公司 | 一种蛋白牛痘疫苗及其效力检测方法 |
| CN113347993A (zh) * | 2018-10-22 | 2021-09-03 | 艾赛澳克莱克斯疗法有限责任公司 | 突变牛痘病毒及其用途 |
| CN111474339A (zh) * | 2020-04-17 | 2020-07-31 | 浙江康佰裕生物科技有限公司 | 一种利用荧光标记痘病毒颗粒的方法及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194254A (en) * | 1986-05-06 | 1993-03-16 | Connaught Laboratories Limited | Enhancement of antigen immunogenicity |
| WO1994006469A1 (en) * | 1992-09-18 | 1994-03-31 | La Jolla Institute For Allergy And Immunology | Hiv fusion polypeptide |
| WO1996040941A1 (en) * | 1995-06-07 | 1996-12-19 | Connaught Laboratories Limited | Chimeric antibodies for delivery of antigens to selected cells of the immune system |
| CA2223577A1 (en) * | 1995-06-07 | 1996-12-19 | Connaught Laboratories Limited | Chimeric antibodies for delivery of antigens to selected cells of the immune system |
| US6224870B1 (en) * | 1997-01-24 | 2001-05-01 | Genitrix, Ltd. | Vaccine compositions and methods of modulating immune responses |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US6958214B2 (en) * | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
| CN102174108B (zh) | 2002-03-01 | 2016-06-29 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
| US7432342B2 (en) * | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
| US7906118B2 (en) * | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US20050003403A1 (en) * | 2003-04-22 | 2005-01-06 | Rossi Edmund A. | Polyvalent protein complex |
| BRPI0607486B8 (pt) * | 2005-03-03 | 2021-05-25 | Immunomedics Inc | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. |
| AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| WO2006113927A2 (en) * | 2005-04-20 | 2006-10-26 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| CA2607056C (en) * | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| AU2006330051B2 (en) * | 2005-12-16 | 2011-08-18 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
| JP5699362B2 (ja) * | 2008-04-10 | 2015-04-08 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | 薬物動態が改善された四量体サイトカインをドック・アンド・ロック（ｄｎｌ）技術により調製するためのモジュール法 |
-
2010
- 2010-10-29 AU AU2010315432A patent/AU2010315432A1/en not_active Abandoned
- 2010-10-29 CA CA2776563A patent/CA2776563A1/en not_active Abandoned
- 2010-10-29 WO PCT/US2010/054668 patent/WO2011056721A2/en active Application Filing
- 2010-10-29 IN IN2692DEN2012 patent/IN2012DN02692A/en unknown
- 2010-10-29 CN CN2010800474188A patent/CN102573902A/zh active Pending
- 2010-10-29 EP EP10828938.0A patent/EP2496256A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011056721A2 (en) | 2011-05-12 |
| EP2496256A4 (en) | 2013-07-17 |
| WO2011056721A3 (en) | 2011-10-13 |
| AU2010315432A1 (en) | 2012-04-12 |
| CN102573902A (zh) | 2012-07-11 |
| CA2776563A1 (en) | 2011-05-12 |
| EP2496256A2 (en) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02692A (ru) | ||
| MX2021011687A (es) | Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas. | |
| MX350274B (es) | Vacunas para hsv-2. | |
| MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
| DK2280721T3 (da) | Indoleamin-2, 3-dioxygenasebaseret immunterapi | |
| IN2014DN10288A (ru) | ||
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| WO2012034025A3 (en) | Human cytomegalovirus vaccine | |
| WO2007008918A3 (en) | Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof | |
| WO2007034489A3 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| PT1951300E (pt) | Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| WO2008103819A3 (en) | Chimeric newcastle disease virus vlps | |
| MX2019003156A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| NZ601609A (en) | Vaccine vectors and methods of enhancing immune responses | |
| ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
| CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
| MX2018000023A (es) | Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina. | |
| CR11537A (es) | Vacuna | |
| WO2007127372A3 (en) | Genetic adjuvants for viral vaccines |